Revamping Cosmetics Oversight: FDA Implements MoCRA Regulations
The U.S. Food and Drug Administration (FDA) is ushering in a new era of cosmetics oversight. Through the Modernization of Cosmetics Regulation Act (MoCRA), the FDA is introducing sweeping changes that will significantly impact the $200 billion beauty and wellness market. These major compliance milestones are set to take effect progressively until 2026.
Key regulatory developments under MoCRA include:
- Mandatory facility registration and product listing for all cosmetic manufacturers
- Adverse event reporting requirements
- The anticipated release of Good Manufacturing Practice (GMP) regulations
Moreover, the FDA has postponed the proposed rule on fragrance allergen disclosure until May 2026. The new requirements are expected to mandate transparency for common allergens on product labels.
On a parallel note, the FDA is moving towards the potential approval of Bemotrizinol (BEMT), a next-generation UV filter. This ingredient, which has been used in Europe for over 20 years, promises to offer superior broad-spectrum sun protection compared to the currently approved U.S. sunscreen ingredients.
Several states, including Maine, Vermont, and Connecticut, have implemented PFAS bans in cosmetics. This has created a fragmented regulatory landscape, compelling brands to adhere to the strictest state-level standards.
For more information, visit the source article: How MoCRA is Reshaping FDA Oversight of Cosmetics by 2026.